Search results
Results From The WOW.Com Content Network
The systems of the body most affected by chemotherapy drugs include visual and semantic memory, attention and motor coordination and executive functioning. [9] [10] These effects can impair a chemotherapy patient's ability to understand and make decisions regarding treatment, perform in school or employment and can reduce quality of life. [10]
Beyond breasts, survivors can experience overnight menopause, infertility, lingering chemo brain, and more. There’s also an emotional toll, which often intensifies over time.
Up to 75% of people who undergo chemotherapy for cancer experience “brain fog” or “chemo brain.” ... could keep you alive — can take away a life worth living, without the means to ...
Olivia Munn is in medically induced menopause as a result of treatment to keep her breast cancer from recurring, the actress told People in an exclusive new interview. Munn, who last month ...
Motor and autonomic symptoms are less frequent but possible. Symptoms may start days after the patient receives their first dose of chemotherapy, are dose dependent, and tend to improve after completion of treatment. However, in some cases, symptoms can persist six months or later following the completion of chemotherapy. [8]
Lomustine is also a lipid soluble, which allows it to permeate the blood brain barrier well. This quality made it a reasonable candidate for the chemotherapy of intrinsic brain tumors. Lomustine is administered orally in six-to-eight-week intervals and with nadirs at five weeks after administration due to its delayed myelosuppressive properties ...
You may have heard of ‘chemo brain;’ some chemo patients describe experiencing memory problems, difficulty concentrating, and a feeling of mental fogginess during or after chemotherapy.”
Temozolomide is an alkylating agent used to treat serious brain cancers; most commonly as second-line treatments for astrocytoma and as the first-line treatment for glioblastoma. [4] [6] [7] Olaparib in combination with temozolomide demonstrated substantial clinical activity in relapsed small cell lung cancer. [8] It is available as a generic ...